Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study

• Published in: Blood advances 2024-10, Vol.8 (20), p.5237-5247
• Main Authors: Matsumura, Itaru, Ohtake, Shigeki, Atsuta, Yoshiko, Kurata, Mio, Minami, Yosuke, Takahashi, Naoto, Nakaseko, Chiaki, Iriyama, Noriyoshi, Fujimaki, Katsumichi, Kakihana, Kazuhiko, Ogasawara, Yoji, Ono, Takaaki, Okada, Masaya, Tauchi, Tetsuzo, Miyamoto, Toshihiro, Ohnishi, Kazunori, Sakaida, Emiko, Fujisawa, Shin, Kobayashi, Yukio, Asou, Norio, Naoe, Tomoki, Kiyoi, Hitoshi, Miyazaki, Yasushi
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Dasatinib - administration & dosage; Dasatinib - therapeutic use; Female; Fusion Proteins, bcr-abl - genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Male; Middle Aged; Myeloid Neoplasia; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Treatment Outcome; Young Adult
• ISSN: 2473-9529; 2473-9537; 2473-9537
• DOI: 10.1182/bloodadvances.2024012655

•Second generation tyrosine kinase inhibitors are more effective than imatinib for de novo CML-CP.•It is important to clarify which tyrosine kinase inhibitors is best to achieve DMR required for TFR. [Display omitted] Deep molecular response (DMR) is a prerequite for treatment-free remission (TFR) in chronic myeloid leukemia in chronic phase (CML-CP). The JALSG (Japan Adult Leukemia Study Group) conducted a prospective randomized phase 3 CML212 study for de novo CML-CP to compare the cumulative achievement of molecular response 4.5 (MR4.5; international scale BCR::ABL1 ≤0.0032%) by 18 months between nilotinib and dasatinib treatment as a primary end point. A total of 454 patients were randomly assigned to the 300 mg nilotinib twice daily arm or to the 100 mg dasatinib daily arm (both n = 227). BCR::ABL1 messenger RNA levels were monitored every 3 months. Study treatment was stopped if the patients were judged as failure according to the European LekemiaNet 2009 criteria or showed intolerance. The cumulative achievement rates of MR4.5 by 18 months were 32.6% (95% confidence interval [CI], 26.5-39.1) in the nilotinib arm and 30.8% (95% CI, 24.9-37.3) in the dasatinib arm with no significant difference (P = .66). The cumulative achievement rates of early molecular response, complete cytogenetic response, and major molecular response by 12, 18, 24, and 36 months were almost the same between the 2 arms. There was no significant difference in progression-free survival (PFS) or overall survival (OS) between the 2 arms by log-rank tests (PFS, P = .58; OS, P = .64). These results suggest that nilotinib and dasatinib would be equally effective for patients with de novo CML-CP. This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry as #UMIN000007909.